Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Cash from Investing Activities (2019 - 2025)

AVITA Medical (RCEL) has disclosed Cash from Investing Activities for 5 consecutive years, with $11000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 99.55% year-over-year to $11000.0, compared with a TTM value of $12.5 million through Dec 2025, down 66.67%, and an annual FY2025 reading of $12.5 million, down 66.67% over the prior year.
  • Cash from Investing Activities was $11000.0 for Q4 2025 at AVITA Medical, up from -$5.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $21.8 million in Q3 2023 and bottomed at -$57.3 million in Q4 2023.
  • Average Cash from Investing Activities over 4 years is $2.0 million, with a median of $7.2 million recorded in 2024.
  • Peak annual rise in Cash from Investing Activities hit 361.27% in 2023, while the deepest fall reached 1714.57% in 2023.
  • Year by year, Cash from Investing Activities stood at -$3.2 million in 2022, then tumbled by 1714.57% to -$57.3 million in 2023, then soared by 104.31% to $2.5 million in 2024, then crashed by 99.55% to $11000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for RCEL at $11000.0 in Q4 2025, -$5.3 million in Q3 2025, and $7.0 million in Q2 2025.